Pacira Pharmaceuticals Inc (PCRX) : Drw Securities added new position in Pacira Pharmaceuticals Inc during the most recent quarter end. The investment management firm now holds 10,100 shares of Pacira Pharmaceuticals Inc which is valued at $459,651 , the company said in a statement filed on Aug 15, 2016 with the SEC.Pacira Pharmaceuticals Inc makes up approximately 0.14% of Drw Securities’s portfolio.
Other Hedge Funds, Including , Zacks Investment Management sold out all of its stake in PCRX during the most recent quarter. The investment firm sold 4,938 shares of PCRX which is valued $224,728. First Mercantile Trust Co sold out all of its stake in PCRX during the most recent quarter. The investment firm sold 9,303 shares of PCRX which is valued $423,380. Acrospire Investment Management added PCRX to its portfolio by purchasing 200 company shares during the most recent quarter which is valued at $8,622. Pacira Pharmaceuticals Inc makes up approx 0.01% of Acrospire Investment Management’s portfolio. Quadrant Capital Group sold out all of its stake in PCRX during the most recent quarter. The investment firm sold 96 shares of PCRX which is valued $3,480.Simplex Trading boosted its stake in PCRX in the latest quarter, The investment management firm added 7,137 additional shares and now holds a total of 8,656 shares of Pacira Pharmaceuticals Inc which is valued at $333,516. Pacira Pharmaceuticals Inc makes up approx 0.04% of Simplex Trading’s portfolio.
Pacira Pharmaceuticals Inc opened for trading at $39.79 and hit $40.48 on the upside on Thursday, eventually ending the session at $40.37, with a gain of 1.87% or 0.74 points. The heightened volatility saw the trading volume jump to 5,38,672 shares. Company has a market cap of $1,505 M.
On the company’s financial health, Pacira Pharmaceuticals Inc reported $0.21 EPS for the quarter, beating the analyst consensus estimate by $ 0.16 according to the earnings call on Aug 4, 2016. Analyst had a consensus of $0.05. The company had revenue of $69.60 million for the quarter, compared to analysts expectations of $66.92 million. The company’s revenue was up 17.8% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.20 EPS.
Many Wall Street Analysts have commented on Pacira Pharmaceuticals Inc. Pacira Pharmaceuticals Inc was Downgraded by Brean Capital to ” Hold” on Jul 1, 2016. Shares were Reiterated by Wedbush on May 25, 2016 to “Outperform” and Lowered the Price Target to $ 105 from a previous price target of $113 .
Pacira Pharmaceuticals Inc. is a specialty pharmaceutical company. The Company is focused on the development commercialization and manufacture of pharmaceutical products based on its DepoFoam drug delivery technology primarily for use in hospitals and ambulatory surgery centers. Its primary focus lies in the development of non-opioid products for postsurgical pain control. DepoFoam is basis for the company’s lead product candidate EXPAREL a liposome injection of bupivacaine an amide-type local anesthetic indicated for infiltration into the surgical site to produce postsurgical analgesia. In addition to EXPAREL DepoFoam is also the basis for its other commercial product DepoCyt(e) which the Company manufactures for its commercial partners as well as its other product candidates. The Company’s other product candidates include DepoMeloxicam and DepoTranexamic Acid.